Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05797324
Other study ID # 21A011
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 17, 2020
Est. completion date December 31, 2023

Study information

Verified date April 2023
Source Istituto Auxologico Italiano
Contact Riccardo Cremascoli
Phone +393497292068
Email r.cremascoli@auxologico.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Some evidence indicates that circadian rhythm may play a role in the pathophysiology of insomnia disorder. This single-blind randomized controlled multicentre prospective study aims to evaluate the possible therapeutic effect of light therapy in modulating the clinical phenotype of patients affected by chronic primary and comorbid insomnia, through the modification of the circadian phase.


Description:

Some evidence indicates that circadian rhythm may play a role in the pathophysiology of insomnia disorder. This single-blind randomized controlled multicentre prospective study aims to evaluate the possible therapeutic effect of light therapy in modulating the clinical phenotype of patients affected by chronic primary and comorbid insomnia, through the modification of the circadian phase. STUDY DESIGN AND METHODS With regard to the study in question, it should be noted that: - the study is a prospective multicentre randomized single-blind controlled trial - the duration of the study is expected to be 3 years with a duration of enrollment of 2 and a half years and a minimum clinical follow-up of 3 months The study will be divided into two evaluations, an initial evaluation (Time 0, T0) where the patients will be enrolled and all the measurements required before treatment with light therapy will be performed, and a final evaluation after 6 weeks of treatment with light therapy effective or sham (Time 1, T1), where the measurements performed at T0 will be repeated. Both assessments will be performed at the Sleep Medicine outpatient clinic. TIME T0 - The diagnosis of primary chronic or comorbid insomnia will be made during the semi-structured sleep interview by a physician expert in sleep medicine, according to DSM V criteria, supported by clinical scales (Insomnia Severity Index, Pittsburgh Quality Index). The presence of mood/behavioral disorders or cognitive deficits will also be excluded (Beck, Stai, Mini Mental Scale Examination). - A home polysomnography will be performed to rule out the presence of sleep apnea disorder or periodic limb movement syndrome during sleep - Circadian parameters (chronotype, Mid sleep, circadian phase, phase angle) will be evaluated in basal conditions through clinical scales (Morning Eveningness Questionnaire, Light diet), measurement of salivary melatonin using evening 5-point wipes at home (DLMO, Elisa) and the actigraphic registration extended for 7 days. - The associations between the circadian phase and the various phenotypes of primary or comorbid insomnia will be then evaluated, according to the duration and the severity of insomnia. - Patients without ocular contraindications will then undergo a Luminotherapy protocol (intermittent blue-enriched light therapy with Luminette 10000 lux equivalent) with morning or evening timing, depending on the circadian phase, or sham treatment (control subgroup; white light <100 lux equivalent). - Patients will be randomly assigned to one of two conditions (treatment and sham). The randomization list will be generated with a simple randomization method through the use of a "Random number generator" software available at www.regione.emilia-romagna.t/sin_info/generatore. The algorithm used in this site coincides with a Lehmer generator (multiplicative congruential generator). Allocation concealment is guaranteed by a central randomization in a distant and independent location with respect to the recruitment site. TIME T1 > After 6 consecutive weeks of home light therapy, patients will be re-evaluated with the same somnometry battery used at study entry. Furthermore, the actigraphic monitoring and the dosage of salivary melatonin will be repeated, to evaluate the variations of the circadian phase and of the sleep-wake pattern after light therapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Primary chronic insomnia - Comorbid chronic insomnia - Absence of pharmacological therapy of insomnia - Absence of behavioural and cognitive treatment of insomnia - Capacity to understand the study and adhere to the procedures - Written informed consent Exclusion Criteria: - Secondary insomnia due to medical conditions or drug treatment - Cerebral diseases - Invalidating diseases - Eye diseases that contraindicate the use of light therapy - Psychiatric disorders - Cognitive decline - Working in night shifts during the last month before enrolment - Impossibility to provide informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Luminette
Luminotherapy protocol (intermittent blue-enriched light therapy with Luminette 10000 lux equivalent) with morning or evening timing, depending on the circadian rhythm
Sham
Sham protocol (white light <100 lux equivalent).

Locations

Country Name City State
Italy Istituto Auxologico Italiano Oggebbio

Sponsors (3)

Lead Sponsor Collaborator
Istituto Auxologico Italiano Ente Ospedaliero Cantonale, Ticino, Switzerland, IRCCS National Neurological Institute "C. Mondino" Foundation

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Insomnia Severity Index Insomnia Severity Index (ISI, Pittsburgh Quality Index) - self-report questionnaire composed of 19 items assessing sleep quality Baseline and after 6 weeks of intervention
Secondary Change in salivary melatonin Salivary melatonin - evening 5-point wipes (DLMO, Elisa) Baseline and after 6 weeks of intervention
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05561829 - Determination of Optimal Sleep Treatment Elements - MOST N/A
Completed NCT05561790 - Determination of Optimal Sleep Treatment Elements - Pilot N/A
Recruiting NCT06053840 - An Open-label Trial to Evaluate the Safety and Efficacy of Chloral Hydrate in Patients With Severe Insomnia Phase 4
Terminated NCT04059302 - Internet Cognitive Behavioral Therapy for Insomnia to Prevent Cardiovascular Disease N/A
Recruiting NCT04545606 - Targeting Insomnia in School Aged Children With Autism Spectrum Disorder N/A
Completed NCT04073992 - Chronic Insomnia and CSF Markers of Dementia - Effects of Treatment N/A
Completed NCT03623438 - Self-administered Acupressure for Insomnia Disorder N/A
Completed NCT04565223 - Feasibility and Acceptability of Cognitive Behavioral Therapy for Chronic Insomnia in a Primary Care N/A
Not yet recruiting NCT06351839 - Sleep Well Despite Persistent Pain Symptoms N/A
Completed NCT05078112 - Sleep Device Testing N/A
Active, not recruiting NCT05917379 - The Safety and Efficacy of FMT in Patients With CID Phase 1/Phase 2
Active, not recruiting NCT04627480 - Evaluation of a Neurostimulation Device for Insomnia: A Randomized Trial Phase 4
Completed NCT03441191 - Audio-visual Stimulation for Sleep Promotion in Older Adults With Osteoarthritis Pain N/A
Completed NCT04406103 - Protocol - Your Answers When Needing Sleep in New Brunswick N/A
Recruiting NCT05373537 - Treatment to Improve Sleep in Caregivers With Insomnia and a Child With Autism N/A
Completed NCT02967185 - Intraindividual Variability in Sleep and Cognitive Performance in Older Adults Phase 2
Recruiting NCT06410495 - Digital Dyadic Family Based Intervention to Improve Sleep in Children With ODD and Their Parents: NiteCAPP SINCC (Pilot) N/A
Completed NCT03015766 - Auricular Acupressure for Hemodialysis Patients With Insomnia N/A
Completed NCT03482856 - Cognitive Behavioural Therapy for Insomnia in Chronic Spinal Pain N/A
Completed NCT03569865 - Audio-visual Stimulation: Sleep Dose Response N/A